05). The HP&PHVHF group was superior to the CVVH group in CRP, APACHE II score (P  less then  .01), and heart rate (HR), WBC, PCT, SOFA (P  less then  .05). The doses of norepinephrine were also decreased after treatment (P  less then  .01), with more reduction in the HP&PHVHF group (P  less then  .05). https://www.selleckchem.com/products/cefodizime-sodium.html After 24 h of treatment, the levels of IL-6, IL-10, and TNF-α decreased in both groups (P  less then  .05), and the decrease was more significant in HP&PHVHF group (P  less then  .05). In combined group, after 2 h of hemoperfison, there was a significant reduction in these inflammatory factors (P  less then  .01). Combined therapy group's mortality was 26.7%, while CVVH group's was 40%.HP combined with PHVHF has a significant effect on septic shock and can be an important therapy for septic shock.Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether aspirin therapy lowers the risk of HCC in patients with alcoholic cirrhosis.A retrospective analysis of data from 949 consecutive patients with alcoholic cirrhosis who abstained from alcoholic drinking was performed. The primary and secondary outcomes were development of HCC and gastrointestinal bleeding events, respectively. Risk was compared between patients with aspirin treatment and patients who were not treated (non-aspirin group) using a time-varying Cox proportional hazards model for total population and propensity score-matching analysis.The aspirin group included 224 patients and the non-aspirin group had 725 patients. During the study period of median duration of 3.1 years, 133 patients (13.6%) developed HCC. In time-varying Cox proportional analyses, the aspirin group showed a significantly lower risk of HCC (adjusted hazard ratio [aHR] 0.13; 95% confidence interval [CI] 0.08-0.21; P  less then  .001). In propensity score-matched pairs, aspirin therapy significantly reduced the risk of HCC (aHR 0.14; 95% CI 0.09-0.22; P  less then  .001). In bleeding risk, treatment with aspirin alone was not significantly associated with a higher bleeding risk (aHR 0.81; 95% CI 0.45-1.44; P = .46).Aspirin therapy was associated with the lower risk of HCC in patients with alcoholic cirrhosis.BACKGROUND Intranasal dexmedetomidine is a relatively new way to sedate young children undergoing nonpainful diagnostic procedures. We performed a meta-analysis to compare the efficacy and safety of intranasal dexmedetomidine in young children with those of oral chloral hydrate, which has been a commonly used method for decades. METHODS We searched PubMed, Embase, and the Cochrane Library for all randomized controlled trials that compared intranasal dexmedetomidine with oral chloral hydrate in children undergoing diagnostic procedures. Data on success rate of sedation, onset time, recovery time, and adverse effects were extracted and respectively analyzed. RESULTS Five studies with a total of 720 patients met the inclusion criteria. Intranasal dexmedetomidine provided significant higher success rate of sedation (relative risk [RR], 1.12; 95% confidence interval [CI], 1.02 to 1.24; P = .02; I = 74%) than oral chloral hydrate. Furthermore, it experienced significantly shorter onset time (weight mean difference [WMD], -1.79; 95% CI, -3.23 to -0.34; P = .02; I = 69%). Nevertheless, there were no statistically differences in recovery time (WMD, -10.53; 95% CI, -24.17 to 3.11; P = .13; I = 92%) and the proportion of patients back to normal activities (RR, 1.11; 95% CI, 0.77-1.60; P = .57; I = 0%). Intranasal dexmedetomidine was associated with a significantly lower incidence of nausea and vomiting (RR, 0.05; 95% CI, 0.01-0.22; P  less then  .0001; I = 0%) than oral chloral hydrate. Although adverse events such as bradycardia, hypotension and hypoxia were not synthetized due to lack of data, no clinical interventions except oxygen supplementation were required in any patients. CONCLUSION Our meta-analysis revealed that intranasal dexmedetomidine is possibly a more effective and acceptable sedation method for infants and toddlers undergoing diagnostic procedures than oral chloral hydrate. Additionally, it shows similar safety profile and could be a potential alternative to oral chloral hydrate.BACKGROUND Glioblastomas are malignant brain tumors associated with high mortality and poor prognosis. Evidence from preclinical studies suggests that statins have an antitumor role, but their effects on the survival of patients with glioblastoma remain controversial. This meta-analysis attempts to assess the association between statins and glioblastoma. METHODS We searched 4 databases (PubMed, Web of Science, Embase, and Cochrane Library) for articles that evaluate the effect of statins on the survival of patients with glioblastoma. Two reviewers were asked to assess the quality of the studies and extract the data regarding progression-free survival (PFS) and overall survival (OS). RESULT A total of 5 studies met the inclusion criteria with 430 statin users and 2089 nonstatin users. All 5 studies were retrospectively analyzed. The pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated. There was no benefit of statins found pertaining to the survival of glioblastoma patients in both PFS (HR, 0.97; CI, 0.84-1.13) and OS (HR, 0.98; CI, 0.87-1.11). In a subgroup defined by the patterns of statin use, it was determined that usage before glioblastoma diagnosis favored the OS of patients (HR, 0.85). The result, however, failed to demonstrate a statistically significant difference. CONCLUSION Use of statins was not associated with prolonged survival of patients with glioblastoma. Further well-designed randomized controlled trials are needed to confirm.BACKGROUND This study aims to assess the quality and safety of life in patients with chronic rhinosinusitis (CRS) treated by acupuncture. METHODS An extensive database search was executed to find the randomized controlled trials on acupuncture vs. sham acupuncture, and any other treatments for patients with CRS. Review Manager 5 (RevMan) was used for the data analysis. A strict methodology was used when the meta-analysis was performed. RESULTS This study systematically assesses the effectiveness and safety of acupuncture in patients with CRS. The primary outcomes include health-related quality of life, disease severity, treatment-related adverse events. The secondary outcomes are comprised of recurrence rate, endoscopic score, computerized tomography (CT) scan score and objective physiological measures. CONCLUSION This article summarizes the current evidence base for the quality of life and safety of acupuncture in patients with CRS. SYSTEMATIC REVIEW REGISTRATION International Prospective Register of Systematic Reviews PROSPERO (registration number CRD42018114432).